The pruritus experienced by patients with ALGS is among the most severe in any chronic liver disease and is present in most affected children by the third year of life. Maralixibat is a minimally-absorbed, orally administered drug that inhibits the apical sodium dependent bile acid transporter, which results in more bile acids being excreted in the faeces, leading to lower levels of bile acids systemically.